208 related articles for article (PubMed ID: 31984451)
1. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
Smith DC; Kroiss M; Kebebew E; Habra MA; Chugh R; Schneider BJ; Fassnacht M; Jafarinasabian P; Ijzerman MM; Lin VH; Mohideen P; Naing A
Invest New Drugs; 2020 Oct; 38(5):1421-1429. PubMed ID: 31984451
[TBL] [Abstract][Full Text] [Related]
2. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
[TBL] [Abstract][Full Text] [Related]
3. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
[TBL] [Abstract][Full Text] [Related]
4. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
5. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
El-Maouche D; Merke DP; Vogiatzi MG; Chang AY; Turcu AF; Joyal EG; Lin VH; Weintraub L; Plaunt MR; Mohideen P; Auchus RJ
J Clin Endocrinol Metab; 2020 Aug; 105(8):2771-8. PubMed ID: 32589738
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.
Liu-Chittenden Y; Jain M; Kumar P; Patel D; Aufforth R; Neychev V; Sadowski S; Gara SK; Joshi BH; Cottle-Delisle C; Merkel R; Yang L; Miettinen M; Puri RK; Kebebew E
Cancer Med; 2015 Jul; 4(7):1060-8. PubMed ID: 25767039
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
9. [Morphological predictors of the efficacy of mitotane therapy in adrenocortical cancer].
Tkachuk AV; Beltsevich DG; Porubayeva EE; Urusova LS
Probl Endokrinol (Mosk); 2023 Jan; 68(6):76-88. PubMed ID: 36689714
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial.
Carneiro BA; Konda B; Costa RB; Costa RLB; Sagar V; Gursel DB; Kirschner LS; Chae YK; Abdulkadir SA; Rademaker A; Mahalingam D; Shah MH; Giles FJ
J Clin Endocrinol Metab; 2019 Dec; 104(12):6193-6200. PubMed ID: 31276163
[TBL] [Abstract][Full Text] [Related]
13. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
O'Sullivan C; Edgerly M; Velarde M; Wilkerson J; Venkatesan AM; Pittaluga S; Yang SX; Nguyen D; Balasubramaniam S; Fojo T
J Clin Endocrinol Metab; 2014 Apr; 99(4):1291-7. PubMed ID: 24423320
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.
Campbell MT; Balderrama-Brondani V; Jimenez C; Tamsen G; Marcal LP; Varghese J; Shah AY; Long JP; Zhang M; Ochieng J; Haymaker C; Habra MA
Lancet Oncol; 2024 May; 25(5):649-657. PubMed ID: 38608694
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
16. ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs.
LaPensee CR; Mann JE; Rainey WE; Crudo V; Hunt SW; Hammer GD
Endocrinology; 2016 May; 157(5):1775-88. PubMed ID: 26986192
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Berruti A; Sperone P; Ferrero A; Germano A; Ardito A; Priola AM; De Francia S; Volante M; Daffara F; Generali D; Leboulleux S; Perotti P; Baudin E; Papotti M; Terzolo M
Eur J Endocrinol; 2012 Mar; 166(3):451-8. PubMed ID: 22189997
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.
Xie H; Yin J; Shah MH; Menefee ME; Bible KC; Reidy-Lagunes D; Kane MA; Quinn DI; Gandara DR; Erlichman C; Adjei AA
Invest New Drugs; 2019 Aug; 37(4):755-762. PubMed ID: 31172443
[TBL] [Abstract][Full Text] [Related]
20. Long-term complete remission of metastatic adrenocortical carcinoma.
Cárdenas-Salas J; Castelo B; Regojo RM; González-Sanchez JA; Álvarez-Escolá C
Horm Mol Biol Clin Investig; 2023 Mar; 44(1):67-71. PubMed ID: 36069780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
